Tivic Health Systems, INC 8-K filings

Valion Bio's subsidiary Velocity Bioworks successfully completed an initial feasibility evaluation of LarmorBio's BioScan-NMR platform, showing potential for real-time bioprocess monitoring.

Valion Bio highlights its subsidiary Velocity Bioworks' capabilities to support domestic biologics manufacturing amid new tariffs, positioning it as a strategic asset for early-phase development.

Valion Bio, Inc. has entered into a letter agreement with 3i, LP to issue 50 shares of Series B Preferred Stock and accompanying warrants for $50,000, furthering its financing efforts.

Valion Bio announces Thomas H. Jensen as new Board Chair, bringing extensive biotech turnaround experience to advance Entolimod's development for acute radiation syndrome.

Valion Bio and Shear Kershman Laboratories have successfully completed formulation work for an oral mucosal Entolimod delivery system, potentially expanding its application beyond injections.

Valion Bio, Inc. announced leadership changes, appointing Dean Zikria as Interim CEO and restructuring its Board of Directors to enhance organizational alignment and strategic execution.

Valion Bio, Inc. announced a 1-for-25 reverse stock split, effective August 31, 2026, to regain compliance with Nasdaq's minimum bid price requirement and maintain its listing.

Valion Bio, Inc. announced final voting results from its special meeting, confirming stockholder approval for the board to implement a reverse stock split.

Valion Bio, Inc. announced a material definitive agreement for Series B Preferred Stock purchase, appointed a new COO, and disclosed preliminary results for a reverse stock split proposal.

Valion Bio reports progress in its Entolimod program, focusing on biodefense preparedness, domestic manufacturing scale-up, and oncology expansion.

Valion Bio, Inc. announced the issuance of Series B Preferred Shares and warrants to 3i, LP for $250,000, as part of a larger potential financing.

Valion Bio, Inc. announced that its stockholders approved an amendment to its 2021 Equity Incentive Plan, increasing the authorized shares by over 2.5 million.

Valion Bio (formerly Tivic Health) reported first quarter 2026 financial results, highlighting progress in its Entolimod platform, government engagement, and integration of Velocity Bioworks.

Valion Bio, Inc. announced the appointment of Melinda Lackey as General Counsel and Senior Vice President of Legal Affairs, bringing extensive biopharmaceutical legal experience to the company.

Tivic Health Systems is rebranding to Valion Bio, Inc. to reflect its strategic pivot from medical devices to a late-stage biopharmaceutical platform.

Tivic Health Systems, Inc. announced its strategic shift to an immunotherapy company, focusing on its Entolimod platform and reporting increased net losses for 2025.

Tivic Health Systems, Inc. received a Nasdaq notification for failing to meet the minimum bid price requirement, initiating a 180-day compliance period.

Tivic Health Systems, Inc. expands its operational footprint by entering into three significant long-term lease agreements for laboratory, biomanufacturing, and office space in San Antonio, Texas.

Tivic Health Systems, Inc. announced the appointment of Michael K. Handley as its new CEO, signaling a strategic pivot towards late-stage immunotherapeutics and biomanufacturing.

Tivic Health Systems, Inc. has acquired substantially all assets of Scorpius Holdings, Inc. for $16.25 million in cash, following Scorpius's default on secured debt and subsequent delisting from NYSE American.

Tivic Health Systems, Inc. has entered into a Common Stock Purchase Agreement with Tumim Stone Capital, LLC, providing access to up to $50 million in equity financing.

Tivic Health Systems, Inc. presented its late-stage TLR5 Agonist portfolio, Entolimod and Entolasta, targeting multi-billion dollar markets in radiation damage and oncology with significant differentiation.

Tivic Health Systems, Inc. has acquired manufacturing and development assets from Scorpius Holdings, Inc., forming a new CDMO subsidiary, Velocity Bioworks, backed by over $90 million in debt and convertible preferred equity financing.

Tivic Health Systems, Inc. announced it has secured a Techwatch meeting with BARDA to discuss its lead drug candidate, Entolimod, for acute radiation syndrome.

Tivic Health Systems, Inc. announced its third quarter 2025 financial results and a strategic pivot to focus solely on its biopharma pipeline, winding down its ClearUP consumer health business.

Tivic Health Systems, Inc. announced findings from its Clinical Optimization Study, demonstrating enhanced autonomic effects through personalized non-invasive vagus nerve stimulation.

Tivic Health Systems, Inc. has formalized a new executive employment agreement with CEO Jennifer Ernst, outlining updated compensation and severance terms.

Tivic Health Systems, Inc. has appointed Odyssey Transfer and Trust Company as its new transfer agent and registrar, effective August 30, 2025, replacing Equiniti Trust Company, LLC.

Tivic Health Systems, Inc. announced the completion of the transfer of two investigational new drug applications (INDs) for its lead candidate, Entolimod, from Statera Biopharma, Inc.

Tivic Health Systems reports Q2 2025 results, highlights strategic pivot to biopharmaceuticals and exits consumer healthtech.